Table V.
Factors affecting weight gain according to univariate analysis.
| Factors | Percentage of weight gain (%) | OR (95% CI) | P-value |
|---|---|---|---|
| Age (years) | |||
| ≤40 | 44.4 | 1.429 (1.040–5.099) | 0.028 |
| 40–50 | 25.0 | 1 | |
| ≥50 | 25.0 | 0.955 (0.623–1.463) | 0.830 |
| Weight (kg) | |||
| ≤50 | 50.0 | 1 | |
| 50–60 | 39.9 | 0.583 (0.226–1.509) | 0.236 |
| ≥60 | 10.1 | 2.211 (1.580–8.321) | 0.023 |
| Menopausal status | |||
| Premenopausal | 31.0 | 1 | |
| Postmenopausal | 27.8 | 1.034 (0.414–2.581) | 0.943 |
| Receptor status | |||
| ER or PR+/HER2+ | 26.7 | 0.800 (0.209–3.064) | 0.744 |
| ER or PR+/HER2− | 26.1 | 1 | |
| ER or PR−/HER2+ | 23.5 | 0.591 (0.298–1.175) | 0.131 |
| ER or PR−/HER2− | 38.5 | 1.507 (0.482–4.710) | 0.367 |
| Stage | |||
| I | 24.1 | 1 | |
| II | 36.1 | 0.933 (0.443–1.968) | 0.855 |
| III | 33.3 | 1.190 (0.461–3.071) | 0.717 |
| Chemotherapy regimens | |||
| Anthracycline-based | 22.2 | 1 | |
| Anthracycline combined with taxane | 33.3 | 1.653 (0.958–2.850) | 0.077 |
| Chemotherapy cycles (no.) | |||
| <4 | 22.5 | 1 | |
| ≥4 | 41.8 | 1.591 (1.166–2.034) | 0.039 |
| Hormone dosage (mg) | |||
| ≤100 | 20.5 | 1 | |
| 100–200 | 41.7 | 1. 639 (1.500–3.520) | 0.024 |
| ≥200 | 40.9 | 2.750 (1.080–7.000) | 0.013 |
OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.